Essity Buys Brazil’s Carefree and Sempre Livre for US$284 Million
Key Facts
- —What happened Swedish hygiene group Essity is buying Kenvue’s Brazilian feminine care business for US$284 million.
- —How big a jump The deal covers Carefree, Sempre Livre and o.b., with yearly sales near US$155 million.
- —The catch The price excludes a factory, staff and distribution, so it is under twice annual revenue.
- —Who it touches Brazilian shoppers keep the brands, but the deal needs CADE approval and another transaction first.
- —What comes next Essity expects the sale to close in the second quarter of 2027, not before.
A Swedish company most Brazilians have never heard of is about to own three products they buy every month.
Essity, the Swedish hygiene group behind Tempo tissues and Libresse pads, is buying Kenvue’s feminine care business in Brazil. The price is US$284 million.
What Essity is actually buying
The deal covers three brands sold in almost every Brazilian pharmacy and supermarket. They are Carefree, Sempre Livre and o.b.
Between them they cover sanitary pads, panty liners and tampons. Essity is also taking the manufacturing equipment that produces them in Brazil.
Essity announced the deal at 19:00 Central European Time on 19 August 2026. It came as a formal stock market statement.
Kenvue keeps the rest of its Brazilian brands. This is the sale of one product line, not an exit from the country.
The price, and what it buys
Essity put the purchase price at US$284 million, or roughly 2.7 billion Swedish kronor. The wording is “on a cash and debt-free basis”.
That phrase matters. It means the buyer is valuing the business itself, not the cash sitting in its bank account.
For the twelve months to 30 June 2026, the business had net sales of about 800 million reais. At the Banco Central PTAX rate of 5.1714 reais to the dollar on 19 August 2026, that is close to US$155 million.
Essity gave the price in Swedish kronor for its own shareholders. The dollar figure is the one most readers will recognise.
Live Market IntelligenceBrazil — Live Market Board
Rio Times · Live Market Intelligence
Brazil — Live Market Board
+2.63%
192,114.55
+2.63%
64,531.68
+1.10%
10,916.57
+0.08%
2,767,663
+0.32%
2,515.02
-0.59%
59,751.67
+0.18%
| Instrument | Last | Change | YoY | Prev. | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| IBOV | 192,114.55 | +2.63% | +21.85% | 187,197.46 | 168,310 | 167,142 | — |
| USD/BRL | 5.16 | +0.01% | -5.13% | 5.16 | 5.18 | 5.14 | — |
| SELIC | 14.00% | — | — | — | — | — | |
| PETR4 | 41.64 | -0.05% | +35.19% | 41.66 | 41.97 | 41.15 | 41,499,400 |
| VALE3 | 72.97 | +0.83% | +30.75% | 72.37 | 73.54 | 72.66 | 17,658,000 |
| ITUB4 | 38.60 | -1.03% | +4.57% | 39.00 | 39.34 | 38.39 | 29,487,800 |
| BBDC4 | 16.85 | +0.36% | +3.50% | 16.79 | 16.90 | 16.67 | 19,416,900 |
| BBAS3 | 19.37 | +0.47% | +0.73% | 19.28 | 19.44 | 19.16 | 11,069,200 |
| B3SA3 | 14.26 | -0.21% | +12.73% | 14.29 | 14.47 | 14.11 | 33,037,800 |
| ABEV3 | 14.89 | -0.80% | +21.91% | 15.01 | 15.07 | 14.81 | 16,453,100 |
| WEGE3 | 47.59 | +0.49% | +29.99% | 47.36 | 48.08 | 47.36 | 3,364,600 |
| PRIO3 | 59.14 | -0.19% | +50.67% | 59.25 | 59.81 | 58.74 | 3,325,600 |
| SUZB3 | 41.33 | +2.35% | -23.55% | 40.38 | 41.48 | 40.35 | 3,914,900 |
| RENT3 | 34.68 | -0.09% | +0.84% | 34.71 | 34.96 | 34.35 | 7,979,100 |
| AZZA3 | 15.89 | -2.63% | -53.76% | 16.32 | 16.42 | 15.82 | 1,330,300 |
| CSNA3 | 4.30 | +0.47% | -42.65% | 4.28 | 4.41 | 4.26 | 10,076,100 |
| GGBR4 | 24.69 | +2.19% | +51.38% | 24.16 | 24.85 | 24.18 | 7,047,600 |
| ENEV3 | 24.21 | -1.38% | +70.49% | 24.55 | 24.64 | 23.99 | 9,297,000 |
Why the price looks low
US$284 million against US$155 million of yearly sales is a little under twice revenue. For brands with this much shelf space, that is not a rich price.
The likely reason is what is not included. Essity is buying brands and equipment, not a full factory with its own land, staff and distribution network.
Buyers pay less for a business they still have to fit into their own operations. They also pay less when the seller is in a hurry.
None of this makes the price a bargain by itself. It makes it a price for a specific, limited set of assets.
Why Kenvue is selling
Kenvue is the consumer health company spun out of Johnson & Johnson. It owns Band-Aid, Listerine and Neutrogena.
Essity said the deal depends on a separate Kimberly-Clark and Kenvue transaction closing first. So this sale is one piece of a much larger reshuffle.
That linkage is why closing is so far away. Essity expects the deal to complete in the second quarter of 2027.
Kenvue has not published its own valuation of the Brazilian unit. The only number on the record came from the buyer.
What has to happen first
Essity is buying assets from several Kenvue subsidiaries. The deal needs approval from regulators in Brazil.
That means CADE, Brazil’s competition watchdog, will look at it. Essity already sells feminine care products in Brazil under other names.
Approval is not automatic when a buyer already competes in the same aisle. It is also not usually a serious obstacle at this size.
Deals of this size rarely fail on competition grounds in Brazil. They more often stall on timing, as this one already has.
What changes for shoppers
In the short term, nothing. Brands rarely change name, packaging or price on the day ownership transfers.
The deal will not close until 2027, and the products stay on the shelf throughout. Any rebranding would come later.
The more common pattern is quiet. A new owner keeps the name that people trust and changes the things they cannot see.
Essity already sells hygiene products in Brazil. Consolidating three well-known names under one owner reduces the number of independent competitors on the shelf.
That is a slow effect rather than a sudden one. It shows up in promotions and pack sizes long before it shows up in a price tag.
Why this matters for foreign residents
Brazil’s consumer market keeps drawing European buyers even when the currency is weak. That is a signal about volume, not about the exchange rate.
Essity is a listed Swedish company that reports in kronor. A Brazilian purchase this size shows Brazil still passes the tests such companies set before they invest.
For anyone following Brazilian consumer shares, it is also a guide to what such brands are worth. Deals like this set the price other owners will ask.
It also says something about how European companies read Brazilian demand. They are buying market share rather than building it.
The numbers to watch next
Essity has not published a breakdown of the three brands’ individual sales. Nor has it said how many people work on the business in Brazil.
Kenvue has not published a figure of its own. The only price on the record is Essity’s.
CADE’s review will eventually produce a public file. Those files usually carry market share estimates the companies would not otherwise publish.
For now the timetable is the story. A deal announced in August 2026 that closes in mid-2027 has a long way to run.
More: Brazil news in English, every day from The Rio Times.
Sources
Frequently Asked Questions
How much is Essity paying?
US$284 million, or about 2.7 billion Swedish kronor, for the business itself, not counting its cash or debt.
Which brands are included?
Carefree, Sempre Livre and o.b., covering sanitary pads, panty liners and tampons, plus related manufacturing equipment in Brazil.
When does the deal close?
Essity expects closing in the second quarter of 2027. It needs Brazilian regulatory approval and the completion of a separate Kimberly-Clark and Kenvue transaction.
Will prices in Brazilian shops change?
Nothing changes now. The deal does not close until 2027, and new owners of established consumer brands usually keep the name and the price point.
How big is the business being sold?
Net sales were about 800 million reais in the twelve months to 30 June 2026. That is roughly US$155 million at the 19 August 2026 PTAX rate of 5.1714.
This article was produced by The Rio Times’ automated newsroom system. How we use AI · Report an error · Editorial responsibility: Matthias Camenzind, Editor-in-Chief